RAAJ MEDISAFE INDIA LTD. (RAAJMEDI) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of RAAJ MEDISAFE INDIA LTD. stock ₹45.49, price ₹102, that is 55.3% below the price, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range ₹18.35 – ₹121.43 · fair‑value band ₹23.24 – ₹61.89 · the ₹101.80 price screens above the ₹45.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow RAAJ MEDISAFE INDIA in your weekly email
Every Wednesday you see whether RAAJ MEDISAFE INDIA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
RAAJ MEDISAFE INDIA LTD. (RAAJMEDI) currently trades at ₹101.80, while our model-based Fair Value estimate is ₹45.49, 55% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹57.16 per share, and 1 of the 14 models we run sit above the ₹101.80 price.
Bear case: the Asset-Based group reads lowest at ₹19.07, and 13 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹23.24 (bear) to ₹61.89 (bull), the price of ₹101.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Health Care sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
RAAJ MEDISAFE INDIA LTD. reported revenue of ₹800M in FY2026 versus ₹347M in FY2022, a compound +23.2%/yr. Reported net income was ₹18.1M in FY2026, compounding −12.0%/yr from FY2022.
Key figures
Market cap ₹1.7B (≈ $17.8M) Micro · P/E ratio 50.9 · P/S ratio 1.79 · EPS (TTM) ₹2.00 · Net margin 2.5% · Return on equity 4.9% · Return on assets (EBIT) 14.7% (5-year average) · Operating margin 11.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 57% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −49% fair-value upside, at −55%, RAAJMEDI screens richer than that median.
Fair Value models
Bear₹23.24Fair Value ₹45.49Bull₹61.89
Price ₹101.80 · Downside -55.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹1.22 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+28.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.5%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−10.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.8%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 12%
Compare RAAJ MEDISAFE INDIA LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Supplies” was too small, so the broader sector is used.)Health Care · 2276 stocks
Beats the sector median on 4/12 measures
Overall it trails its sector peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−55.3% · Below median
Profitability
Return on equity (12 months)4.9% · Above median
Return on assets1.5% · Below median
Net margin (12 months)2.5% · Below median
Operating margin (12 months)11.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)86.1% · Top 25%
Balance sheet
Debt / equity0.78× · Highest 25%
Valuation Multiplesvs Health Care median · lower = cheaper
P/E (12 months)50.9× · Priciest 25%
P/B3.58× · Priciest 25%
P/S (12 months)1.79× · Cheaper than median
EV/EBITDA14.6× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 5
FUTURE (revenue growth)100· sector 31
PAST (return on equity)20· sector 18
HEALTH (low debt)61· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "RAAJ MEDISAFE INDIA LTD. Fair Value". https://www.fairvalue-calculator.com/stock/RAAJMEDI
Frequently asked questions
Is RAAJ MEDISAFE INDIA LTD. (RAAJMEDI) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of ₹45.49 versus a price of ₹101.80, about 55% lower (overvalued).
What is the fair value of RAAJMEDI?
Our model-based fair value for RAAJ MEDISAFE INDIA LTD. is ₹45.49 (as of Nov 4, 2026), built from audited fundamentals. The current price: ₹101.80.
What is the quality score of RAAJMEDI?
RAAJ MEDISAFE INDIA LTD. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
Our model-based price target is the fair value of ₹45.49 (as of Nov 4, 2026) from 14 valuation models. Cautious scenario ₹23.24, optimistic scenario ₹61.89. It is a calculation from audited fundamentals, not an analyst target.
What is the RAAJ MEDISAFE INDIA LTD. stock forecast for 2026?
Our models put fair value at ₹45.49, about 55% lower versus a price of ₹101.80 (overvalued). Cautious scenario ₹23.24, optimistic scenario ₹61.89. The calculation is refreshed regularly with new filings.
What is the revenue of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
RAAJ MEDISAFE INDIA LTD. reported trailing-twelve-month revenue of about ₹936M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RAAJ MEDISAFE INDIA LTD. it is ₹45.49 per share (as of Nov 4, 2026), against a price of ₹101.80. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is RAAJ MEDISAFE INDIA LTD. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, RAAJMEDI trades above its calculated fair value: price ₹101.80, fair value ₹45.49, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RAAJMEDI?
No. The price is what the market pays today (₹101.80); the fair value is what the company's own numbers justify (₹45.49). For RAAJ MEDISAFE INDIA LTD. the two are ₹56.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is RAAJ MEDISAFE INDIA LTD. worth?
The market values RAAJ MEDISAFE INDIA LTD. at about ₹1.7B (market capitalisation, as of Nov 4, 2026). Per share that is ₹101.80; our models calculate a fair value of ₹45.49 per share.
What do the bullish and bearish scenarios say about RAAJMEDI?
Our models span a range for RAAJ MEDISAFE INDIA LTD.: cautious scenario ₹23.24, base ₹45.49, optimistic ₹61.89 per share (as of Nov 4, 2026, price ₹101.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RAAJMEDI?
RAAJ MEDISAFE INDIA LTD. trades at a price-to-earnings ratio of 50.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹45.49 is built from several models across several years. Other multiples: P/B 3.6, P/S 1.8, EV/EBITDA 14.6.
How solid is the balance sheet of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
Balance-sheet figures for RAAJ MEDISAFE INDIA LTD. (as of Nov 4, 2026): return on equity 4.9%, debt of 0.78 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is RAAJMEDI from its 52-week high?
RAAJ MEDISAFE INDIA LTD. trades at ₹101.80, about 4% below its 52-week high of ₹106.56 and 57% above the low of ₹64.78 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ₹45.49 is for.
Which stocks are comparable to RAAJ MEDISAFE INDIA LTD.?
From the same area (Health Care) we also value PINC, SHUKRAPHAR, KMCSHIL, TITANBIO, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RAAJ MEDISAFE INDIA LTD. stock attractive at the current price?
The data as of Nov 4, 2026: price ₹101.80, calculated fair value ₹45.49 (−55%), Quality Score 33/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RAAJMEDI calculated?
We run RAAJ MEDISAFE INDIA LTD. through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹45.49 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. RAAJ MEDISAFE INDIA LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
The closing price on Nov 6, 2026 was ₹101.80. Our model-based fair value is ₹45.49, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RAAJ MEDISAFE INDIA LTD. right now?
The price sits above even our optimistic bull case (₹61.89). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (₹23.24 to ₹61.89). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of RAAJ MEDISAFE INDIA LTD.
How large is the market capitalisation of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
The market capitalisation of RAAJ MEDISAFE INDIA LTD. is ₹1.7B (≈ $17.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
The price-to-sales ratio of RAAJ MEDISAFE INDIA LTD. is 1.79 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
Earnings per share at RAAJ MEDISAFE INDIA LTD. are ₹2.00 (price ÷ EPS = P/E 50.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
The net margin of RAAJ MEDISAFE INDIA LTD. is 2.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
The return on equity (ROE) of RAAJ MEDISAFE INDIA LTD. is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
On an EBIT basis the return on assets of RAAJ MEDISAFE INDIA LTD. is 14.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
The operating margin of RAAJ MEDISAFE INDIA LTD. is 11.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
Revenue at RAAJ MEDISAFE INDIA LTD. is growing +86.1% versus a year earlier (3y avg +27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at RAAJ MEDISAFE INDIA LTD. (RAAJMEDI)?
Earnings per share at RAAJ MEDISAFE INDIA LTD. are growing +8.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does RAAJ MEDISAFE INDIA LTD. (RAAJMEDI) generate?
The free cash flow of RAAJ MEDISAFE INDIA LTD. is −₹298M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does RAAJ MEDISAFE INDIA LTD. (RAAJMEDI) carry?
The net debt of RAAJ MEDISAFE INDIA LTD. is ₹517M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch RAAJ MEDISAFE INDIA LTD. in the live analysis
One click puts RAAJ MEDISAFE INDIA LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 4, 2026